文献速递鼻科

内镜鼻窦术后预防性抗生素的随机双盲安慰剂对照非劣效试验

Prophylactic antibiotics after endoscopic sinus surgery for chronic rhinosinusitis: a randomized, double-blind, placebo-controlled noninferiority clinical trial.
PubMed 文献 · Int Forum Allergy Rhinol · 2020-12-19

本研究为随机双盲安慰剂对照非劣效试验,纳入77例药物难治性慢性鼻窦炎行内镜鼻窦手术的成人,比较阿莫西林-克拉维酸与安慰剂。结果显示安慰剂在术后SNOT-22评分上非劣于抗生素,内镜评分轨迹和感染率无显著差异,但抗生素组腹泻率显著更高。

要点

  • 安慰剂在术后SNOT-22评分上非劣于预防性抗生素。
  • 两组内镜评分轨迹和术后感染率无显著差异。
  • 抗生素组腹泻率显著高于安慰剂组。

核心结论

  • 安慰剂在术后鼻窦特异性生活质量方面非劣于预防性抗生素。
  • 术后内镜评分和感染率两组无显著差异,但抗生素组腹泻率显著更高。

研究设计与样本

  • 随机双盲安慰剂对照非劣效试验(NCT01919411)。
  • 纳入77例药物难治性慢性鼻窦炎行内镜鼻窦手术的成人,抗生素组37例,安慰剂组40例。

主要发现

  • 术后SNOT-22评分安慰剂非劣于抗生素(β=0.18,双侧p<0.05)。
  • 内镜Lund-Kennedy评分随时间变化两组无显著差异(p=0.63)。
  • 术后感染率抗生素组2.6% vs 安慰剂组2.4%(p=0.96)。
  • 腹泻发生率抗生素组24.3% vs 安慰剂组2.5%(相对风险=10.8,p=0.02)。

关键数值与推荐

  • 非劣效性检验基于术后SNOT-22评分(β=0.18,双侧p<0.05)。
  • 腹泻发生率抗生素组24.3% vs 安慰剂组2.5%(相对风险=10.8,p=0.02)。

临床怎么用

  • 常规术后预防性抗生素未改善内镜鼻窦手术后结局,且显著增加腹泻。
  • 该结果支持重新评估内镜鼻窦术后预防性抗生素的常规使用。

局限性

  • 研究统计效能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgeons commonly prescribe prophylactic antibiotics after endoscopic sinus surgery (ESS), yet minimal data exist to support this practice. In this study we aimed to assess the impact of post-ESS antibiotics on infection, quality of life (QOL), and endoscopic scores. METHODS: This was a randomized, double-blind, placebo-controlled, noninferiority trial comparing amoxicillin-clavulanate vs placebo after ESS (NCT01919411, ClinicalTrials.gov). Adults (N = 77) with chronic rhinosinusitis (CRS) refractory to appropriate medical therapy who underwent ESS were randomized to antibiotics (N = 37) or placebo (N = 40) and followed clinically (mean ± standard deviation: 1.3 ± 0.3 and 8.8 ± 3.9 weeks postoperatively). At baseline and follow-up, QOL was measured with 22-item Sino-Nasal Outcome Test questionnaires and Lund-Kennedy endoscopic scores were evaluated. Outcomes were analyzed with repeated-measures analysis of variance and analysis of covariance and z tests for proportions. RESULTS: Placebo was noninferior to antibiotic prophylaxis with regard to postoperative SNOT-22 scores (β = 0.18, 2-tailed p < 0.05). There were no significant differences between the antibiotic and placebo groups in LK score trajectories over time (p = 0.63) or in postoperative infection rates (2.6% vs 2.4%, respectively; p = 0.96). The rate of diarrhea was significantly higher in the antibiotic group (24.3% vs 2.5%; relative risk = 10.8; p = 0.02). CONCLUSION: Although statistically underpowered, the results suggest placebo was noninferior to prophylactic antibiotics after ESS for CRS regarding postoperative sinonasal-specific QOL. There were no significant differences in postoperative endoscopic scores or rates of infection, but the rate of diarrhea was significantly higher in the antibiotic group. These findings add to the growing evidence that routine use of prophylactic postoperative antibiotics does not improve outcomes post-ESS and significantly increases the rate of diarrhea.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Lehmann AE, Raquib AR, Siddiqi SH, et al. Prophylactic antibiotics after endoscopic sinus surgery for chronic rhinosinusitis: a randomized, double-blind, placebo-controlled noninferiority clinical trial. Int Forum Allergy Rhinol. 2020. PMID: 33340285. doi:10.1002/alr.22756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。